This document is a publication of a European Patent application (EP4709729A1) by Jazz Pharmaceuticals Ireland Ltd. It details pyrazoloquinazoline derivatives identified as modulators of G12D mutant KRAS, useful for the treatment of cancer. The publication includes a list of inventors and IPC classifications related to organic chemistry, medicinal preparations, and cancer treatment.

This patent publication does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in oncology research and development, as it pertains to intellectual property in the field of cancer therapeutics. Compliance officers in the pharmaceutical sector should note this patent as it may impact future drug development strategies and competitive landscapes.